Anti-tumor effects of anti-CD3ε Fab fragments depend on tumor antigen availability

---

Presentation Time: 11:30 AM - 12:45 PM
Poster Board Number: B211
Abstract ID: 5444

Presenting Author:
Hien Huynh , Graduate Student at Univ. of Missouri, Columbia, Univ. of Missouri, Columbia

Abstract:

We previously demonstrated anti-CD3ε Fabs bound to the CD3 complex enhanced the response of monoclonal T cells when their T cell receptors engaged poorly immunogenic antigens, without stimulating responses from T cells with antigen-unengaged receptors or interrupting responses to strongly immunogenic antigens. We named this effect “T cell co-potentiation”.  Anti-CD3ε Mono-Fabs also co-potentiate the capacity of T cells to control tumor progression, observed when administering the Fabs to B6 mice with poly-clonal T cells implanted intra-venously with the syngeneic melanoma B16F10. Using another B6 syngeneic set of melanoma cell lines, the YUMM/ER1.7, which includes variants of increasing potential to present tumor associated antigens (TAAs), we have now established the contribution of such antigens, the integrity of the CD3ε CXXC motif, and the patterns of effector T cell subpopulations required to support anti-tumor effects by anti-CD3ε Mono-Fabs when injected into melanoma bearing mice.